Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083577
Status:
COMPLETED
Last Update Posted:
2010-07-02
First Post:
2004-05-25
Brief Title:
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
Sponsor:
University of Arkansas
Organization:
University of Arkansas
Study Overview
Official Title:
UARK 98-003 A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide
Detailed Description:
Patients will receive thalidomide in the oral form by mouth Then the dose of thalidomide will be increased each week until week 7 as long as there are no significant side effects After week 7 patients will continue to receive thalidomide as long as there is no toxicity requiring the treatment to be stopped and as long as there is no evidence of rapid tumor growth during the treatment with thalidomide
Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered if any and provide the available treatments for side effects accordingly Blood tests will be done once a month for the first six months of receiving thalidomide
Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered if any and provide the available treatments for side effects accordingly Blood tests will be done once a month for the first six months of receiving thalidomide
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None